PHI with Liver metastases
How does this condition affect your private health insurance?
Lebermetastasen, or liver metastases, are secondary cancerous tumors originating from a primary cancer elsewhere in the body that have spread to the liver. The liver is a common site for metastasis due to its rich blood supply. These metastases indicate advanced-stage cancer, significantly impacting prognosis. Symptoms may include fatigue, weight loss, jaundice, and abdominal pain. Diagnosis involves imaging like CT, MRI, and PET scans, often with biopsies. Treatment focuses on disease control, symptom relief, and improving quality of life, commonly utilizing chemotherapy, targeted therapies, immunotherapy, radiation, or surgical resection in select cases.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Often discovered as part of an advanced cancer diagnosis; initial diagnostic and staging procedures can take days to weeks, followed by immediate treatment initiation.
Duration of Illness (Lifetime)
Typically a chronic, life-limiting condition, often managed over months to years depending on the primary cancer and extent of disease.
Cost of Treatment (Initial)
High, involving extensive diagnostics (imaging, biopsies), multidisciplinary consultations, and initiation of systemic therapies (chemotherapy, targeted therapy) or local treatments, potentially tens of thousands of dollars.
Cost of Treatment (Lifetime)
Very high, as treatment is often ongoing, involving multiple lines of systemic therapy, supportive care, and repeat imaging, often escalating to hundreds of thousands of dollars or more.
Mortality Rate
High (typically >80-90% within 5 years for most widespread cases), as it signifies advanced, often incurable, systemic cancer. Prognosis varies significantly with the primary tumor type and extent.
Risk of Secondary Damages
High, including liver dysfunction, pain, fatigue, cachexia, and significant side effects from aggressive therapies (e.g., neuropathy, bone marrow suppression, organ damage).
Probability of Full Recovery
Very low (<5-10% in highly selected cases, primarily oligo-metastatic colorectal cancer amenable to aggressive resection), as it generally indicates systemic disease.
Underlying Disease Risk
100%, as liver metastases are always secondary to a primary cancer located elsewhere in the body (e.g., colorectal, breast, lung, pancreatic cancer).